PT158.S3.Q9 > Question

SECTION 1 · rc

PASSAGE 1

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7

PASSAGE 2

Question 8 Question 9 Question 10 Question 11 Question 12 Question 13

PASSAGE 3

Question 14 Question 15 Question 16 Question 17 Question 18 Question 19 Question 20

PASSAGE 4

Question 21 Question 22 Question 23 Question 24 Question 25 Question 26 Question 27

SECTION 2 · lr

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7 Question 8 Question 9 Question 10 Question 11 Question 12 Question 13 Question 14 Question 15 Question 16 Question 17 Question 18 Question 19 Question 20 Question 21 Question 22 Question 23 Question 24 Question 25

SECTION 3 · lr

SECTION 4 · lr

A Consumer Advocate argues that the government should require drug companies to notify consumers of all known drug-related interactions. This is because even minor drug-related interactions can be harmful to patients, and people who are unaware of this suffer discomfort or take more pain relievers than necessary.

The Consumer Advocate assumes that patients would utilize this information to benefit themselves, they may not care.

The author also assumes that the inclusion of minor drug-related interactions will not distract/outweigh the importance of the major ones, thereby causing more harm than good.

This weakens the conclusion because it suggests that including more recommendations could lead to patients neglecting more dangerous interactions, causing more harm than good.

Aspirin is pretty irrelevant to the reasoning of the argument. It is really brought up as an example to demonstrate a broader point.

While this provides a potential downside to the legislation, it does not weaken the underlying reasoning for why the author supports it.

This is irrelevant because the argument is concerned with providing information about “known” interactions, not ones that have yet to be identified.

This does not impact the argument's reasoning because the Consumer Advocate is focused on the labels that aren’t currently present. It does not matter if pharmacists are pointing to labels that are already there.

PrepTest 158 - Section 3 - Question 9

Difficulty

Analysis

Answer Popularity

Question history

Confirm action